Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Royer

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
International Journal of Cancer|August 10, 2019
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatinJeanne Galaine, Célia Turco, Charline Vauchy, et al.
Molecular Therapy. Oncology|January 1, 2026
Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalitiesCharles-Frédéric Mantion, Sabeha Biichlé, Xavier Roussel, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosisCécile Molucon-Chabrot, Nicolas Isambert, Laurent Benoit, et al.
Annals of Surgical Oncology|January 7, 2022
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 PatientsBrice Paquette, Elsa Kalbacher, Frédéric Mercier, et al.
Mabs|March 30, 2017
A new anti-mesothelin antibody targets selectively the membrane-associated formKamal Asgarov, Jeremy Balland, Charline Tirole, et al.
British Journal of Clinical Pharmacology|September 15, 2022
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiencyMaud Maillard, Manon Launay, Bernard Royer, et al.
Haematologica|November 9, 2014
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agentFanny Angelot-Delettre, Anne Roggy, Arthur E Frankel, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
International Journal of Cancer|August 10, 2019
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatinJeanne Galaine, Célia Turco, Charline Vauchy, et al.
Molecular Therapy. Oncology|January 1, 2026
Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalitiesCharles-Frédéric Mantion, Sabeha Biichlé, Xavier Roussel, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosisCécile Molucon-Chabrot, Nicolas Isambert, Laurent Benoit, et al.
Annals of Surgical Oncology|January 7, 2022
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 PatientsBrice Paquette, Elsa Kalbacher, Frédéric Mercier, et al.
Mabs|March 30, 2017
A new anti-mesothelin antibody targets selectively the membrane-associated formKamal Asgarov, Jeremy Balland, Charline Tirole, et al.
British Journal of Clinical Pharmacology|September 15, 2022
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiencyMaud Maillard, Manon Launay, Bernard Royer, et al.
Haematologica|November 9, 2014
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agentFanny Angelot-Delettre, Anne Roggy, Arthur E Frankel, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Pageof 7